2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 13, 2019

9:00AM-10:30AM: Abstract Number: 2872

Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database

6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)

9:00AM-10:30AM: Abstract Number: 2877

Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis

6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)

9:00AM-10:30AM: Abstract Number: 2880

Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial

6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)

9:00AM-10:30AM: Abstract Number: 2883

Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases

6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

9:00AM-10:30AM: Abstract Number: 2890

The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study

6W017: Health Services Research II: Health Economics (2888–2893)

9:00AM-10:30AM: Abstract Number: 2858

The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model

6W012: RA – Etiology & Pathogenesis II (2858–2863)

11:00AM-12:30PM: Abstract Number: 2911

A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy

6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: Abstract Number: 2901

Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience

6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: Abstract Number: 2916

Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population

6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: Abstract Number: 2928

Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease

6W026: Epidemiology & Public Health (2924–2929)

11:00AM-12:30PM: Abstract Number: 2929

Cannabis Use Among Patients in a Large US Rheumatic Disease Registry

6W026: Epidemiology & Public Health (2924–2929)

11:00AM-12:30PM: Abstract Number: 2894

CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity

6W022: SLE – Etiology & Pathogenesis II (2894–2899)

11:00AM-12:30PM: Abstract Number: 2907

Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response

6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: Abstract Number: 2923

Clinical Subsets in Giant Cell Arteritis

6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

11:00AM-12:30PM: Abstract Number: 2920

Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis

6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].